Vir Biotechnology News

Komo: Maintaining the Vir Biotechnology (VIR.US) rating, adjusted from neutral to neutral, and adjusted the target price from $10.00 to $12.00.

Zhitong FinanceMay 4 03:20

Needham Reiterates Buy on Vir Biotechnology, Maintains $15 Price Target

BenzingaMay 4 03:15

JP Morgan Maintains Neutral on Vir Biotechnology, Raises Price Target to $12

BenzingaMay 4 03:17

Vir Biotechnology Analyst Ratings

BenzingaMay 4 03:14

Hold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial Uncertainty

TipRanksMay 3 19:12

Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)

TipRanksMay 3 18:42

Buy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment Milestones

TipRanksMay 3 18:27

Vir Biotechnology Analyst Ratings

BenzingaMar 15 21:25

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR) and IN8bio (INAB)

TipRanksMar 15 18:20

Buy Rating Affirmed for Vir Biotechnology on Promising HDV and HBV Programs and Strategic Market Positioning

TipRanksMar 11 12:46

Optimistic Outlook for Vir Biotechnology's Clinical Programs and Financial Position Reinforces Buy Rating

TipRanksFeb 26 12:29

Vir Biotechnology Analyst Ratings

BenzingaFeb 24 01:32

Maintaining Hold on Vir Biotechnology Amid Revenue Decline and Strategic Pivot

TipRanksFeb 23 20:16

Barclays Issues a Buy Rating on Vir Biotechnology (VIR)

TipRanksFeb 23 16:05

Buy Rating Affirmed for Vir Biotechnology on Promising Hepatitis Drug Pipeline and Market Potential

TipRanksFeb 23 13:16

HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $110

BenzingaFeb 14 19:42

Vir Biotechnology Analyst Ratings

BenzingaFeb 14 19:39

JP Morgan Cuts Vir to Neutral, Cites Hepatitis Drug Franchise Concerns

Seeking AlphaJan 30 03:19

Vir Biotechnology Analyst Ratings

BenzingaJan 29 19:04

Vir Biotechnology Analyst Ratings

BenzingaJan 23 19:40